Policy & Regulation
Stay informed about the latest cannabis regulation developments and changes with Business of Cannabis. Learn about new laws, policies and more.
Policy & Regulation · page 9
- UK & Europe
The Battle for Germany’s Medical Cannabis Market: Who’s Fighting for What
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country’s near-billion-euro medical cannabis industry.
- US & Canada
Republican Lawmakers Openly Defy Trump on Cannabis Rescheduling
As the excitement around President Donald Trump’s executive order to push forward with cannabis rescheduling has faded, the bill is now facing a much harsher reality.
- Medical Cannabis
Spanish Pharmacists Appeal Hospital-Only Cannabis Rule as Key Regulatory Deadline Passes Unmet
Spain represents one of the most exciting incoming additions to the European medical cannabis market this year, as one of the continent’s largest producers finally moves toward domestic patient access after years of hard-fought advocacy.
- Industry Trends
Inside the Medical Cannabis Police Guidance: Cancards, Driving, and What Patients Need to Know
Earlier this week, the first official guidance on medical cannabis for police officers in England and Wales was made public.
- Medical Cannabis
UK Police Finally Get Official Medical Cannabis Guidance More Than 7 Years After Legalisation
Over seven years after medical cannabis was legalised in the UK, the National Police Chiefs’ Council has approved the first official guidance for medical cannabis.
- International Regulation
Germany’s Medical Cannabis Bill Faces Critical Test as Experts Warn of ‘Unenforceable’ Framework
As Trump’s rescheduling executive order dominated the cannabis industry’s attention over the holiday period, Germany’s controversial medical cannabis bill quietly entered its most critical phase.
- Clinical Research
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant shift in US drug policy in over half a century.
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- Industry Trends
Could Trump Actually Reschedule Cannabis This Time?
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through the long-touted move via an executive order.
- Industry Trends
Germany’s Hidden Stigma Crisis: Why Pillar 2 is Still Sorely Needed
By: Dr. Sebastián Marincolo, Director of Strategic Content & Editorial, Weed.de Germany’s partial cannabis legalisation was originally designed to undercut the black market.
- Hemp Industry
Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
- CBD Market
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to authorise insurance coverage for CBD products under certain Medicare programs, even as the same products face an existential threat from recently passed federal legislation.
